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Background: Mycophenolate mofetil (MMF) has long been used to manage lupus nephritis. Despite research on its
long-term efficacy, it is still warranted to conduct further investigation regarding its indications, safety and outcome.
This study was intended to evaluate our proposed protocol in maintenance therapy with MMF.
Twenty-four lupus nephritis patients were registered prior to their receiving 3–6 month induction therapy with
monthly iv pulses of cyclophosphamide (CYC), followed by 24 month maintenance therapy using MMF and steroid.
We defined end points as achievement of complete and partial remission, relapse, refractory to therapy as well as
end stage renal disease (ESRD) and death. Friedman and repeated measurement tests were used to assess the
effect of treatment on parameters over time.
Complete renal remission was achieved in 79.16% until the end of the last follow up with an average period of
12.45 ± 7.37 months since treatment commenced. Significant statistical differences were seen regarding proteinuria,
hematuria, leukocyturia, plasma creatinine, C3, C4 before and after therapy (P < 0.05): plasma creatinine and
proteinurea falling from 0.96 ± 0.65 to 0.75 ± 0.19 mg/dl (P < 0.14) and from 1.64 ± 1.12 to 0.27 ± 0.60 gr/24 h
(P < 0.001). By the end of 24-month, 95.8% of patients had been in remission. Four episodes of relapse ended in
remission followed by retreatment. No life-threatening side effects were observed in 66.6% of patients with fourteen
cases of infection (58.3%). None of them developed ESRD.
Maintenance therapy with MMF was shown to yield favorable outcome with minimal complications, in treating
lupus nephritis (IRCT2012071710313N1).
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Renal involvement occurs in approximately 40% of pa-
tients with systemic lupus erythematosus. Nephritis is
the first manifestation of lupus in 3–6% of patients and
the severity of renal injury determines its prognosis.
Generally, survival in lupus patients is roughly 92% at
10 years after diagnosis. Proliferative renal involvement
is among the most severe manifestations of lupus and
without proper treatment it can lead to significant mor-
bidity and mortality (Cameron 1999; Mak et al. 2007;
Korbet et al. 2007; Contreras et al. 2005; Bernatsky et al.
2006; Hahn et al. 2012).
A logical combination of drugs to achieve specific
therapeutic goals is of paramount significance in treating* Correspondence: Rezaieyazdiz@mums.ac.ir
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reproduction in any medium, provided the origlupus nephritis. The core of treatment is based on the
application of drugs with maximum efficacy and mini-
mum toxicity in order to control of nephritis to the
point of allowing a good quality of life, and non progres-
sion of renal disease.
Effective therapy is designed to reduce mortality and
prevent progress to end-stage renal disease. Immuno-
suppressive regimens of glucocorticoids combined with
cytotoxic drugs, particularly cyclophosphamide, was ef-
fective and standard for the treatment of severe prolifer-
ative lupus nephritis (Hahn et al. 2012; Contreras et al.
2004; Ferrantelli et al. 2005; Flanc et al. 2004; Austin
et al. 1986; Illei et al. 2001; Gourley et al. 1996; Steinberg
and Steinberg 2005; Rezaie-Yazdi et al. 2005; Mok et al.
2001; Ioannidis et al. 2000; Grootscholten et al. 2007).
However, cyclophosphamide has both instant and cumu-
lative adverse effects, including marrow suppression, go-
nadal toxicity, hemorrhagic cystitis, and the increasedis is an Open Access article distributed under the terms of the Creative
mmons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
inal work is properly credited.
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relapse in several patients (Houssiau et al. 2002, 2010a).
Therefore, other therapeutic agents, such as azathioprine
and mycophenolate mofetile with few toxic effects, come
prior to other alternatives (Grootscholten et al. 2006;
Arends et al. 2012; Sahin et al. 2008; Houssiau et al.
2010b; Dooley et al. 2011).
Nowadays mycophenolate mofetile has been consid-
ered an important alternate agent for refractory lupus
nephritis with hopeful results and reasonable side effects
(Chan et al. 2000, 2005; Lenz et al. 2005; Weng et al.
2010; Zhu et al. 2007; Ong et al. 2005; Karim et al.
2005). Mycophenolic acid, the active metabolite of my-
cophenolate mofetil , selectively suppresses the prolifera-
tion of T and B lymphocyte, the formation of antibodies,
and the glycosylation of adhesion molecules by inhibiting
purine nucleotide synthesis and depleting lymphocytes
and monocytes of guanosine triphosphate (Eickenberg
et al. 2012). Mycophenolate mofetile as maintenance ther-
apy after short-term intravenous cyclophosphamide have
been shown efficient and safe, reducing the long-term
exposure to cyclophosphamide (Bernatsky et al. 2006;
Flores-Suárez 2006; Borba et al. 2006; Tse et al. 2006).
In comparison with cyclophosphamide the adverse ef-
fects of MMF have been revealed to be well- tolerated,
with gastrointestinal upset being the most common, and
no mutagenic effects (Laskari et al. 2010; Elyan and
Ballou 2009).
The aim of our study was to evaluate the efficacy and
safety of mycophenolate mofetil combined with prednis-
olone for maintenance treatment of lupus nephritis in a
single center cohort of patients with proliferative lupus
nephritis.
Patients & methods
In this open label clinical trial twenty four consecutive
patients with the diagnosis of lupus in accordance with
ACR classification criteria (Tan et al. 1982) were en-
rolled and prospectively followed up during 24 months.
All patients had the criteria for nephritis. Renal biopsy
was done for 20 patients. Every specimen was observed
under light microscopy, the findings of which were sub-
sequently categorized based on the revised World Health
Organization (WHO) classification for lupus nephritis
(Weening et al. 2004).
Inclusion criteria were defined by one of the followings:
– Evidence of active proliferative glomerulonephritis in
the renal biopsy (WHO class IV, III)
– In case of absent renal biopsy or the presence of
WHO class V in biopsy, with the presence of the
following clinical or paraclinical findings:a) Proteinaria >1 gr/24 hb) Progressive renal failure with 30% decrease in
creatinine clearance over one-year period and
creatinine >1.9 mg/dL
c) The presence of more than 5 red cells in HPF
of urine sediment in two separate specimens
taken in a year, presence of WBC, granular or
hyaline casts without active infection (was
examined under conventional light microscope)Exclusion criteria include:
WHO class I or II lupus nephritis, end stage renal
disease when replacement renal therapy will be
indicated, leukopenia (neutrophils < 1500/mm3) due to
bone marrow suppression, recurrent episodes of
bacterial infection, history of cytotoxic drug treatment
for more than two weeks or pulse therapy with
corticosteroids during a six-week period before study
entry.
Study protocol and immunosuppressive treatment
For classes III and IV of lupus nephritis, the treatment
considered as four phases:
1) Induction: intravenous cyclophosphamide, given as
boluses once a month for 3–6 consecutive
months (to the maximum dose of 1 g/m2) in
addition to corticosteroid. All patients received
ondansetron to prevent nausea and vomiting
with every CYC pulse. High dose glucocorticoid
was initiated with ivtravenous pulse
methylprednisolon (500–1000 mg given over
30 minutes daily for three days) then changed to
oral prednisolon (40–60 mg) for one month,
tapered to intermediate dose during maintenance
phase of therapy.
2) Maintenance: mycophenolate mofetil (cellcept®,
manufactured by Zahravi Pharm.Co, Under License
of F. Hoffmann-La Roche Ltd, Basel, Switzerland) to
the maximum dose of 2 gr/day combined with
corticosteroid.
3) Tapering: mycophenolate mofetil dosage remains
unchanged for the first year followed by dose
reduction in the second year, in the absence of
relapse or partial remission fulfillment.
When partial remission was achieved, we started
to taper prednisolon by an average of 10%
monthly in order to reach an optimum dose of
5–10 mg/day.
4) Discontinuation: if our study goals had been
achieved, the mycophenolate mofetil would have
been discontinued with the further tapering of
prednisolone to the lowest possible daily dose and
patients’ follow-up for evidence of relapse.
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nolate mofetil combined with corticosteroid since the
diagnosis was made.
Patients were followed up every month during induction
therapy and every other month during the first year and
every three months thereafter. During each visit, the pa-
tients were evaluated including a complete physical exam-
ination as well as all laboratory and serologic tests (blood
count, urine analysis, creatinine, GFR, measurement of
proteinuria in 24 h urine collection, C3, C4, Anti-DNA,
ANA, ESR). At each visit, side effects were investigated via
enquiry and thorough physical examination. Each patient
had a complete clinical evaluation for any other organ in-
volvement besides nephritis as well as episodes of relapse.
Informed consent was obtained from all patients. The
design of the work has been approved by the ethical
committee of Mashhad University of Medical sciences.
End points were defined as
Criteria for complete remission:
a) Complete improvement of renal and extra-renal
symptoms:
Rise of creatinine less than 0.3 mg/dL, less than
300 mg proteinuria per day (only trace proteinuria)
or less than 50% of initial proteinuria when
Cr >1.7 mg/dl, absence of RBC cast, complete
regression of all systemic symptoms
b) Return to within normal limits of ESR, C3, C4, Hb
and fall of autoantibody titers
c) Absence of relapses and infectious complications
Criteria for partial remission:
a) No progression of renal disease (normal or stable
renal function)
b) Decrease of at least 50% in dysmorphic RBC, cellular
casts and proteinuria in the absence of doubling of
serum creatinine or less than 1 gr proteinuria per day
c) Return to within normal limits of markers of
inflammation such as ESR
d) Regression of systemic symptoms
e) Return of patient to functional class 2 in the
presence of an acceptable rate of complications
Relapse:
a) More than 50% increase in (after reaching the lowest
level during therapy) serum creatinine, dysmorphic
RBC, cellular cast
b) Doubling of proteinuria if there was nephritic
proteinuria or at least 2 gr/day if based
proteinuria < 3.5 gr/day
c) At least two systemic symptoms reappearedRefractory to therapy:
a) No renal response in spite of 6 month treatment
with mycophenolate mofetil
End stage renal disease:
a) Plasma creatinine rose and got stabilized above
5 mg/dl for 3 months
Statistical analysis
Analyses of all data were conducted in SPSS version
11.5. The significance of the process of changes of variables
with abnormal distribution was assessed by Friedman test
whereas those with normal distribution were tested by re-
peated measurement.
Wilcoxon signed ranks test was used for comparing
quantitative variables with abnormal distribution while
Paired t-test was applied to variables with normal
distribution. All mean values were shown ±1SD and
P values < 0.05 were considered statistically significant.
Results
Patients’ characteristics
We enrolled 20 females and 4 males with active lupus
nephritis with majority documented with diffuse prolif-
erative glomerulonephritis. Two tissue samples (10%)
were compatible with WHO class III, 13 samples were
WHO class IV (65%) and 5 samples were WHO class V
(25%). Adverse predictive factors such as proteinuria,
low GFR, hypertention, were detected in 95.8%, 33.3%
and 41.6% of patients respectively. At the beginning of
renal disease 21 patients had hematuria and 18 patients
had leukocyturia. The average range of proteinuria be-
fore treatment was 1.57 ± 1 gr/day. Three patients (13%)
had nephrotic syndrome (proteinuria >3gr/day). Decrease
in C3 and C4 levels were seen in 33.30% at the beginning
of therapy. Anti DNA was positive in 50% of patients.
Renal insufficiency means creatinine >1.9 mg/dL was seen
in one patient at the beginning of therapy.
Extra renal manifestations at baseline are as follows:
skin rash 13(54.2%), arthritis 15(62.5%), oral ulcer 16
(66.7%), vasculitis 3(12.5%), nervous system involvement
3(13%), cardiac involvement 1(4.2%) and pneumonitis 1
(4.2%). Baseline characteristics of 24 patients with lupus
nephritis are shown in Table 1.
Results of the statistical comparisons among selected
variables at baseline and at the latest follow up showed
a significant improvement of all parameters including
proteinuria, C3 and C4 (Table 2). Then we evaluated la-
boratory data variables changes during the course of
treatment.
Significant alterations could be observed in proteinuria
which resolved in 20 out of 24 (83.3%) patients (Figure 1),
Table 1 Characteristics of twenty four patients with lupus
nephritis
Characteristics Mean Range
Age (year) 20.7 ± 8.1 10 – 40
Duration between onset of lupus
and renal involvement (month)
15.17 ± 22.79 0 – 84
Serum Creatinine (mg/dl) 0.95 ± 0.63 0.10 – 3.5
GFR(ml/min/1.73 m2) 83.19 ± 32.99 20.40 – 162.91
Urinary protein (g/24 h) 1.57 ± 1.11 0.10 – 4.3
Serum C3 (mg/dl) 63.12 ± 28.46 14 – 120
Serum C4 (mg/dl) 17.19 ± 8.38 6-35
Platlete (number/mm3) 255 ± 93 × 103 63 – 511× 103
Serum Hb (mg/dl) 12.01 ± 1.72 8.8 – 15.9
ESR/h 32.79 ± 28.08 4 – 130
Systolic BP (mmHg) 129.58 ± 22.69 80 – 180
Diastolic BP (mmHg) 86.04 ± 14.25 60 – 120
Urine WBC (n/hpf) 19.25 ± 27.38 0 – 100
Urine RBC (n/hpf) 21.87 ± 31.15 0 – 100
Rezaieyazdi et al. SpringerPlus 2014, 3:638 Page 4 of 8
http://www.springerplus.com/content/3/1/638and hematuria (P < 0.001), whereas parameters such
as platlete count, Hb and ESR seemed immune to dras-
tic changes (P = 0.31, P = 0.88, P = 0.24). The creatinine
level changes during the course of therapy has been
shown in Figure 2 (P = 0.68). As to renal involvement
implications systolic and diastolic blood pressure varied
in their pattern of, with the latter falling substantially
(P = 0.02) while the former remained almost unchanged
(P = 0.09).
As can be seen in the Figure 3, initial response to ther-
apy began since the first month following drug adminis-
tration in accordance with our protocol. Sixteen cases
were shown to match partial remission criteria at the
end of the third month, and one patient achieved full re-
mission; which could first be seen at the end of the third
month, gaining momentum at a sharp pace to peak at
around month 21.Table 2 Statistical comparisons of selected variables prior
to and following treatment
Parameters Before (mean ± SD) After (mean± SD) P value
Proteinuria(gr/24 h) 1.57 ± 1.11 0.27 ± 0.60 <0.001
Hematuria(n/hpf) 21.87 ± 31.15 2.28 ± 3.42 <0.001
Leukocyturia(n/hpf) 19.25 ± 27.38 2.85 ± 5.59 0.001
C3(mg/dl) 63.12 ± 28.46 97.79 ± 20.73 <0.001
C4(mg/dl) 17.19 ± 8.38 23.41 ± 8.47 0.006
Creatinine(mg/dl) 0.96 ± 0.95 0.75 ± 0.19 0.144
GFR(ml/min/1.73 m2) 83.19 ± 32.99 98.96 ± 26.73 0.060Outcome measures
Partial renal remission
With a mean renal remission time of 3.67 ± 2.58 months
from baseline, five out of 24 patients (20.83%) reached
partial renal remission.
Complete renal remission
Complete renal remission was achieved in 19 out of 24
patients (79.16%) at the end of the last follow up. Aver-
age period of complete remission was 12.45 ± 7.37 month
since the beginning of treatment.
At the end of follow-up, 23 out of 24 patients (95.8%)
of the patients had reached remission.
Renal relapse
Relapses occurred during the maintenance phase of ther-
apy in 4 out of 24 patients in remission (16.6%).
Relapses happened at 15th, 18th and 21st months of ther-
apy and all patients except one responded when retreated
with cyclophosphamide pulse followed by mycophenolate
mofetil.
Chronic renal failure-death
There was no refractory-to-therapy case. None of our
patients developed chronic renal insufficiency or died.
Extra renal manifestation and pregnancy
The majority of the initial extra renal manifestations re-
solved during the maintenance phase of therapy. None
of our patients developed sustained amenorrhea. During
this treatment course, we had four patients who had
been pregnant at 8th, 10th, 15th and 21th months since
treatment commenced, when they were in partial remis-
sion, ending in unproblematic delievery. Azathioprine
replased mycophenolate mofetil throught pregnancy per-
iod, with one relapse episode following delivery.
Side effects
Side effects were observed in sixteen out of the 24 pa-
tients (66.6%) with fourteen cases of infection (58.3%).
No hemorrhagic cystitis was observed while transient
gastrointestinal complications affected two patients dur-
ing maintenance therapy (12%) (diarrhea, gastrointes-
tinal discomfort and nausea).
Discussion
Mainstream therapy is primarily intended to improve
renal function as well as to prevent progressive disease.
Mycophenolate mofetil was approved for clinical use in
lupus nephritis over the past years. Several studies have
been conducted on mycophenolate mofetil for mainten-
ance therapy of lupus nephritis (Hahn et al. 2012; Sahin
et al. 2008; Houssiau et al. 2010b; Dooley et al. 2011;


















Figure 1 Proteinuria and its changes during the course of follow up.
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2006; Tse et al. 2006; Laskari et al. 2010; Elyan and Ballou
2009; Ginzler et al. 2005; Mak et al. 2009).
On the basis of anecdotal reports of success with my-
cophenolate mofetil in patients with lupus nephritis with
a considerable likelihood for poor outcomes (Chan et al.
2000, 2005; Lenz et al. 2005; Ginzler et al. 2005), in the
present study we intended to examine the safety and ef-
ficacy of MMF as maintenance therapy for proliferative
lupus nephritis following a short-term induction therapy
with iv CYC. Favorable response with acceptable side ef-
fects were observed in most patients.
Of the 24 patients treated based on our therapeutic
protocol, partial as well as full remission could be achieved
in a significant percentage, 95.8% of the patients, while re-
lapse rates were as low as 16.6%. Our study was free of se-
vere complications such as renal failure and mortality. We
had the acceptable rate of relapse, 16.6% after the 15th
month, during the course of therapy, all of whom treated
with short-course cyclophosphamide pulse therapy and
mycophenolate mofetil to achieved remission. All cases of
relapse were seen one year following the last pulse of
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Figure 2 Creatinin and its changes during the course of follow up.MMF dose was reduced. This may indicate that our pa-
tients might have needed a longer period of treatment in
the second phase. The dose of prednisolon has also been
reduced in the third phase. Relapses could have been de-
layed had steroid been tapered at a slower pace.
One interesting point regarded successful pregnancies
among our patients thought our course of therapy. These
cases were in 10th, 15thand 21st month of treatment when
the patients were in partial remission. Another case was in
her 8th month and in complete remission but lupus neph-
ritis relapsed following delivery.
The response rate to MMF therapy in this study was
significant and compatible with other reports. Similar to
Chan et al. study on 21 and 33 patients who showed
81% and 72.7% complete remission with MMF therapy
(Chan et al. 2000, 2005).
In the study of Elyan and Ballou (Elyan and Ballou
2009) on 25 patients with lupus nephritis treated with
MMF, 57% and 17% of patients achieved complete re-
mission and partial remission in order. On average it
took our cases 3.6 and 12.4 months to achieve partial
and full remission respectively whereas Elyan and Ballou




















Figure 3 The process of changes of patients responses to treatment during the course of follow up.
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C3 and C4 showed significant differences before and after
treatment, with GFR and creatinine changing slightly
which was similar to Elyan and Ballou study (Elyan and
Ballou 2009).
As our only three cases of relapse occurred through-
out the tapering phase, we may safely conclude that
early reduction in steroid and mycophenolate mofetil
dosage can account for them.
However, one case of relapse following delivery can also
be explained owing to replacing MMF with azathioprine.
Alteration trends pertaining to laboratory finding vari-
ables during the course of treatment were also shown al-
most parallel with other reports findings (Laskari et al.
2010; Elyan and Ballou 2009). Ginzler EM et al. pub-
lished multicenter, randomized clinical trial and showed
that MMF is an appropriate alternative to CYC for the
treatment of renal diseases in patients with biopsy-proven
lupus nephritis (Ginzler et al. 2005). Our study was in
agreement with their observations.
In Laskari et al. (2010) study from Greece, thirty-three
consecutive patients with proliferative lupus nephritis re-
ceived oral MMF 2 g/day as maintenance therapy for a
median time of 29 months. They showed a significant
improvement of all renal parameters at the end of the
induction treatment as well as at the latest follow-up
compared to the baseline. Renal remission achievement
rate to the end of the follow-up was 73% whereas it was
54% for complete remission cases. They reported 4
(12%) patients who relapsed within 19–39 months after
initial response. At the end of their follow-up, 51% of
patients had reached remission. Their results were in
agreement with ours except for the fact that we had
fewer side effects in comparison with the Laskari et al.
findings (Laskari et al. 2010).
In our clinical trial, there were only two gastrointes-
tinal complications due to MMF which is generally re-
versible and in comparison with cyclophosphamide sideeffects, seems insubstantial. The majority of women pre-
served ovarian function, with four pregnancies. Bone
marrow suppression was not a complication of MMF in
our study. In contrast to the study by Contreras et al., in
which 1 episode of chronic renal failure and 1 death due
to severe infection happened, such outcomes were not
observed in our cases (Contreras et al. 2004). Some ad-
vantages of this study with regard to well defined criteria
for examined parameters include lower dose of MMF
and long-term follow-up with regular intervals.
The present study suggests that small dose MMF com-
bined with the shortest duration of CYC therapy may be
safer than long-term use of CYC without compromising
efficacy. This investigation had not been intended for
evaluating the effectiveness of MMF as induction ther-
apy in proliferative lupus nephritis. However, there have
been reports highlighting the role of MMF in inducing
remission (Zhu et al. 2007; Mak et al. 2009; Lee et al.
2010; Walsh et al. 2007; Hui et al. 2013). According to
previous data a better outcome with MMF has been de-
monstrated for non-Caucasian patients (Lee et al. 2010),
with considering the fact that our patients were Caucasian,
the present study results may put emphasis on the benefit
and safety of long term use of MMF in Caucasian race.
Future large cohort study of lupus nephritis patients with
well defined and strict criteria for all examined parameters
such as criteria for full remission, partial remission, re-
lapse, flare as well as the opportunity to have long period
of regular follow up would establish our observations.
We were also restricted in terms of the following: As
it was an open label clinical trial, there was no control
group then the possibility of randomization and masking
was not considerable. As continuous follow up and re-
peated observations of variables in different time interval
was performed, so there was possibility of measurements
biases due to mean reversion phenomenon. Moreover,
the limited numbers of patients made it impossible to
generalize our findings in Caucasian race. Other factors
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biopsy after course of treatment.
On the other hand, our study contain valuable data on
the main concern of maintenance treatment in lupus
nephritis given the long period of follow up, the clear
design and regular follow up of all patients. Randomized
controlled trials containing a larger group could corrob-
orate our findings.
In sum, we concluded that mycophenolate mofetil ap-
pear to be efficacious and very safe as maintenance
treatment for proliferative lupus nephritis following
an intensive induction therapy with a short-course of
monthly iv, endoxan pulse. That improved renal re-
mission and reduce relapse rates as well as reduction
in cyclophosphamide toxicity.
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